Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Regorafenib
40
CHF
CHF 40.00
In stock
AG-CR1-3623-M0055 mgCHF 40.00
AG-CR1-3623-M02525 mgCHF 110.00
| Product Details | |
|---|---|
| Synonyms | BAY 73-4506; Fluoro-Sorafenib |
| Product Type | Chemical |
| Properties | |
| Formula |
C21H15ClF4N4O3 |
| MW | 482.8 |
| CAS | 755037-03-7 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Light pink to white solid. |
| Solubility | Soluble in DMSO (>50mg/ml). Slightly soluble in ethanol (1mg/ml). Insoluble in water. |
| Identity | Determined by 1H-NMR |
| InChi Key | FNHKPVJBJVTLMP-UHFFFAOYSA-N |
| Smiles | CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Orally bioavailable potent antitumor, antiangiogenic, antiproliferative and antineoplastic agent.
- Multi-target kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 values of 13, 4.2, 46, 22, 7, 1.5 and 2.5nM, respectively.
Product References
- Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity: S.M. Wilhelm, et al.; Int. J. Cancer 129, 245 (2011)
- Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors: G.D. Demetri; Semin. Oncol. 38, S10 (2011)
- Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib: K.A. Lyseng-Williamson, et al.; BioDrugs 27, 525 (2013) (Review)
- Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors: D.J. Crona, et al.; Ann. Pharmacother. 47, 1685 (2013) (Review)
- Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer: R. Schmieder, et al.; Int. J. Cancer 135, 1487 (2014)
- Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis: Z. Weng, et al.; Toxicology 327, 10 (2015)
- Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling: T. Goncharov, et al.; Mol. Cell. 69, 551 (2018)
Related Products
